Urgent.News

What's breaking now, across hundreds of outlets.

Business

Thyroid Nodule Monitoring Guidance During GLP-1 Treatment: Separating the Warning Label From the Evidence

Thyroid nodules are present in an estimated 50 to 70 percent of adults by age 60, which means a large share of the population starting GLP-1 therapy will already have one, discovered or not, before they ever take a first dose. That baseline prevalence is essential context for interpreting the black box warning that accompanies semaglutide and liraglutide, since it means the presence of a nodule…

Thyroid nodules are a common finding in adults, especially as they age, with an estimated 50 to 70 percent of those over 60 years old having one. This prevalence is crucial to consider when examining the black box warning associated with semaglutide and liraglutide, two GLP-1 therapy medications. The presence of a nodule itself does not necessarily imply a drug-related risk, as the warning is specifically intended to address the extremely rare medullary thyroid carcinoma, a subtype of thyroid cancer.

The warning is based on animal research, where GLP-1 medications caused thyroid C-cell hyperplasia and medullary thyroid carcinoma at higher rates than control groups. However, human studies have not shown that GLP-1 receptor agonists cause common forms of thyroid cancer or worsen existing malignancies. In fact, among semaglutide-treated patients, overall thyroid cancer incidence was less than 1 percent, and medullary thyroid carcinoma was found in only roughly 0.001 cases per 100 patient-years of exposure.

A recent study found no meaningful association between GLP-1 receptor agonist use and increased thyroid cancer risk in the general population. The key distinction that often gets blurred is between benign thyroid nodules, which are common and typically harmless, and medullary thyroid carcinoma, a rare subtype with a specific cause.

Having a nodule during or before GLP-1 therapy does not indicate a higher risk for the cancer the warning targets. Current guidance does not recommend routine neck ultrasounds or calcitonin blood tests for patients without specific symptoms, a family history of medullary thyroid carcinoma, or a known nodule. Testing is only necessary for those who report symptoms or have an identified nodule.

The contraindication for GLP-1 therapy is not a general recommendation but rather applies to patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Proper intake procedures during the prescribing process are essential to identify and exclude this small group of patients, allowing the majority, including those with undiagnosed benign nodules, to proceed with treatment without unnecessary testing.

This screening process, based on medical history rather than physical examination, is crucial for telehealth platforms like TrimRx, which rely on physician-reviewed patient histories before issuing prescriptions. While telehealth may face limitations in obtaining accurate self-reported family history and performing physical exams, it can still effectively apply the necessary screening by asking specific questions about personal and family thyroid cancer history and MEN2.

Rewritten by urgent.news; may contain errors — check the original.

Source: en.mercopress.com

Read the original at en.mercopress.com →

Report a problem with this story

More in Business

More from Friday 6 November →